feedback

Faculty

Kao-Ping Chua, MD, PhD

Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan Medical School, Ann Arbor

Rena M. Conti, PhD

Questrom School of Business, Institute for Health System Innovation and Policy, Department of Markets, Public Policy, and Law, Boston University, Boston, Massachusetts

Accredited by

American Medical Association

View Activity Materials

Course Description

To understand the policy implications of the Orphan Drug Designation for Remdesivir to treat COVID-19

Activity Details

Credit Types:CME
Credit Amount:1.00 Credits
Release Date:2020-Oct-01
Expiration Date:2023-Oct-01
Estimated Time for Completion:1 hour
Registration Required:Yes
Cost:$0.00-$30.00
System Requirements:
CME is free with premium AMA membership.
CME can be purchased individually for $30.00.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.